487 related articles for article (PubMed ID: 15746072)
41. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
42. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
43. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
44. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
45. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
[TBL] [Abstract][Full Text] [Related]
46. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of a new platinum compound, cis-(glycolato-O,O) [(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclohexane]plat inum (II) in dogs.
Kim DK; Cho YB; Kim HT; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(3A):1167-9. PubMed ID: 8702230
[TBL] [Abstract][Full Text] [Related]
48. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Meany HJ; Fox E; McCully C; Tucker C; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.
Fouladi M; Blaney SM; Poussaint TY; Freeman BB; McLendon R; Fuller C; Adesina AM; Hancock ML; Danks MK; Stewart C; Boyett JM; Gajjar A
Cancer; 2006 Nov; 107(9):2291-7. PubMed ID: 17019740
[TBL] [Abstract][Full Text] [Related]
51. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
52. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM
Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
55. Monitoring local disposition kinetics of carboplatin in vivo after subcutaneous injection in rats by means of 195Pt NMR.
Becker M; Port RE; Zabel HJ; Zeller WJ; Bachert P
J Magn Reson; 1998 Jul; 133(1):115-22. PubMed ID: 9654475
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
Luo FR; Wyrick SD; Chaney SG
Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
[TBL] [Abstract][Full Text] [Related]
57. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
58. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
60. [Cis-diamminedichloroplatinum penetration into the cerebrospinal fluid of the lateral ventricle, postoperative cavity, and lumbar subarachnoid space with or without pre-intravenous mannitol administration in patients with brain metastasis from lung cancer].
Nakagawa H; Yamada M; Tamura M; Yoshida M; Shindo M; Nishiyama H; Sakai S
Gan To Kagaku Ryoho; 2014 Mar; 41(3):317-24. PubMed ID: 24743276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]